NPI: 1518347517 · GAINESVILLE, FL 32605 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 06/04/2015
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 06/04/2015 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 2,384 | $516K |
| 2019 | 2,514 | $497K |
| 2020 | 3,207 | $478K |
| 2021 | 546 | $136K |
| 2022 | 449 | $74K |
| 2023 | 2,216 | $179K |
| 2024 | 761 | $86K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 9,370 | 720 | $1.49M |
| J1270 | Injection, doxercalciferol, 1 mcg | 646 | 63 | $156K |
| A4657 | Syringe, with or without needle, each | 542 | 322 | $140K |
| 85048 | 271 | 208 | $49K | |
| 85041 | 271 | 208 | $49K | |
| 83540 | 97 | 79 | $20K | |
| 82728 | 97 | 79 | $20K | |
| 83550 | 97 | 79 | $20K | |
| 83970 | 83 | 63 | $15K | |
| 82108 | 14 | 14 | $4K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 14 | 14 | $4K |
| J1756 | Injection, iron sucrose, 1 mg | 351 | 52 | $0.00 |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 224 | 12 | $0.00 |